Multiple Sclerosis Drugs - United States

United States

The Multiple Sclerosis Drugs market is estimated to generate a revenue of €10.91bn in 2024.
It is anticipated that the revenue will experience a compound annual growth rate (CAGR 2024-2029) of 0.95%, leading to a market volume of €11.44bn by 2029.
Among all the countries worldwide, United States is expected to contribute the highest revenue, with €10.91bn in 2024.
The United States is experiencing a surge in demand for innovative Multiple Sclerosis drugs, driven by advancements in research and a growing patient population.

Key regions: France, India, United Kingdom, South Korea, Japan

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Multiple Sclerosis Drugs market in the United States has been steadily growing in recent years, driven by a variety of factors.

Customer preferences: Patients with multiple sclerosis (MS) in the United States are increasingly seeking out treatments that offer improved efficacy, safety, and convenience. As such, there has been a growing demand for disease-modifying therapies (DMTs) that can slow the progression of MS and reduce the frequency of relapses. Additionally, patients are looking for treatments that are easy to administer, such as oral medications or self-injectable options.

Trends in the market: One of the major trends in the Multiple Sclerosis Drugs market in the United States is the increasing use of oral medications. In recent years, a number of new oral DMTs have been approved for use in the United States, providing patients with more convenient treatment options. Another trend in the market is the growing use of monoclonal antibodies (mAbs) for the treatment of MS. These drugs, which are administered via infusion, offer high levels of efficacy and are often used in patients who do not respond well to other treatments.

Local special circumstances: The United States has a large and aging population, which has contributed to the growth of the Multiple Sclerosis Drugs market. MS is most commonly diagnosed in people between the ages of 20 and 40, and as the population ages, the number of people living with MS is expected to increase. Additionally, the United States has a well-established healthcare system that provides patients with access to a wide range of treatments.

Underlying macroeconomic factors: The Multiple Sclerosis Drugs market in the United States is also influenced by a number of macroeconomic factors. One of the most important of these is the cost of healthcare. MS is a chronic condition that requires ongoing treatment, and the cost of these treatments can be significant. As such, the availability of insurance coverage and the cost of co-pays and deductibles can have a significant impact on the demand for MS treatments. Additionally, the regulatory environment in the United States plays a key role in the development and approval of new MS treatments, which can impact the availability of new drugs in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.